Predictors of recurrence following an initial episode of transverse myelitis

Neurology: Neuroimmunology and NeuroInflammation

Volumn 1, Issue 1, 2014, Pages

  Kimbrough, Dorlan J ^a   Mealy, Maureen A ^a   Simpson, Alexandra ^a   Levy, Michael ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; BLOOD GROUP A ANTIGEN; IMMUNOGLOBULIN G; VITAMIN D;

ADULT; AFRICAN AMERICAN; ANTIBODY TITER; ARTICLE; CEREBROSPINAL FLUID; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELITIS; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SJOEGREN SYNDROME;

EID: 84919698033     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000004     Document Type: Article

References (33)

1. de Seze J, Lanctin C, Lebrun C, et al. Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology. 2005; 65: 1950-1953.
2. Mealy MA, Newsome S, Greenberg BM, Wingerchuk D, Calabresi P, Levy M. Low serum vitamin D levels and recurrent inflammatory spinal cord disease. Arch Neurol. 2012; 69: 352-356.
3. Hummers LK, Krishnan C, Casciola-Rosen L, et al. Recurrent transverse myelitis associates with anti-Ro (SSA) autoantibodies. Neurology. 2004; 62: 147-149.
4. Sellner J, Luthi N, Buhler R, et al. Acute partial transverse myelitis: risk factors for conversion to multiple sclerosis. Eur J Neurol. 2008; 15: 398-405.
5. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007; 6: 805-815.
6. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40: 1725.
7. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64: 2677-2686.
8. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002; 61: 554-558.
9. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66: 1485-1489.
10. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in healthy individuals. Arthritis Rheum. 1997; 40: 1601-1611.
11. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003; 157: 940-943.
12. Sepulveda M, Blanco Y, Rovira A, et al. Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. Mult Scler. 2013; 19: 742-748.
13. Habek M, Adamec I, Pavlisa G, Brinar VV. Diagnostic approach of patients with longitudinally extensive transverse myelitis. Acta Neurol Belgica. 2012; 112: 39-43.
14. Kitley JL, Leite MI, George JS, Palace JA. The differential diagnosis of longitudinally extensive transverse myelitis. Mult Scler. 2012; 18: 271-285.
15. Larik A, Chiong Y, Lee LC, Ng YS. Longitudinally extensive transverse myelitis associated with dengue fever. BMJ Case Rep. 2012; 2012.
16. White C, Leonard B, Patel A. Longitudinally extensive transverse myelitis: a catastrophic presentation of a flareup of systemic lupus erythematosus. CMAJ. 2012; 184: E197-E200.
17. Collongues N, Marignier R, Zephir H, et al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology. 2010; 74: 736-742.
18. Jacob A, McKeon A, Nakashima I, et al. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2013; 84: 922-930.
19. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012; 69: 1176-1180.
20. Nagaishi A, Takagi M, Umemura A, et al. Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurology Neurosurgery Psychiatry. 2011; 82: 1360-1364.
21. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002; 59: 499-505.
22. Kim KK. Idiopathic recurrent transverse myelitis. Arch Neurol. 2003; 60: 1290-1294.
23. Ravaglia S, Bastianello S, Franciotta D, et al. NMO-IgGnegative relapsing myelitis. Spinal Cord. 2009; 47: 531-537.
24. Klein NP, Ray P, Carpenter D, et al. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine. 2010; 28: 1062-1068.
25. Awad A, Stuve O. Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices. Curr Neuropharmacology. 2011; 9: 417-428.
26. Christensen PB, Wermuth L, Hinge HH, Bomers K. Clinical course and long-Term prognosis of acute transverse myelopathy. Acta Neurol Scand. 1990; 81: 431-435.
27. Jeffery DR, Mandler RN, Davis LE. Transverse myelitis. Retrospective analysis of 33 cases, with differentiation of cases associated with multiple sclerosis and parainfectious events. Arch Neurol. 1993; 50: 532-535.
28. Krishnan C, Kaplin AI, Deshpande DM, Pardo CA, Kerr DA. Transverse Myelitis: pathogenesis, diagnosis and treatment. Front Biosci. 2004; 9: 1483-1499.
29. Cabre P, Heinzlef O, Merle H, et al. MS and neuromyelitis optica in Martinique (French West Indies). Neurology. 2001; 56: 507-514.
30. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol. 2003; 2: 117-127.
31. Osuntokun BO. The pattern of neurological illness in tropical AFrica. Experience at Ibadan, Nigeria. J Neurol Sci. 1971; 12: 417-442.
32. Storoni M, Pittock SJ, Weinshenker BG, Plant GT. Optic neuritis in an ethnically diverse population: higher risk of atypical cases in patients of AFrican or AFrican-Caribbean heritage. J Neurol Sci. 2012; 312: 21-25.
33. Takahashi T, Fujihara K, Nakashima I, et al. Anti-Aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain A J Neurol. 2007; 130: 1235-1243.